Charles H. Sherwood Sells 63,799 Shares of Anika Therapeutics Inc. (ANIK) Stock

Anika Therapeutics Inc. (NASDAQ:ANIK) CEO Charles H. Sherwood sold 63,799 shares of the firm’s stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $50.79, for a total value of $3,240,351.21. Following the sale, the chief executive officer now directly owns 174,705 shares of the company’s stock, valued at $8,873,266.95. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Anika Therapeutics Inc. (ANIK) traded down 0.37% during mid-day trading on Thursday, reaching $51.38. The company’s stock had a trading volume of 94,040 shares. The stock has a market cap of $753.13 million, a PE ratio of 22.83 and a beta of 1.69. Anika Therapeutics Inc. has a 52-week low of $41.38 and a 52-week high of $53.99. The company has a 50 day moving average of $49.07 and a 200-day moving average of $47.01.

Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings results on Wednesday, July 26th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.32. Anika Therapeutics had a return on equity of 14.88% and a net margin of 30.44%. The business had revenue of $33.50 million for the quarter, compared to the consensus estimate of $27.20 million. During the same quarter in the prior year, the business posted $0.57 earnings per share. The firm’s quarterly revenue was up 25.9% compared to the same quarter last year. Equities analysts forecast that Anika Therapeutics Inc. will post $2.00 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in ANIK. State Street Corp raised its position in shares of Anika Therapeutics by 3.2% in the fourth quarter. State Street Corp now owns 316,791 shares of the biotechnology company’s stock valued at $15,507,000 after buying an additional 9,917 shares in the last quarter. FMR LLC acquired a new stake in shares of Anika Therapeutics during the fourth quarter worth $1,772,000. Thrivent Financial for Lutherans increased its stake in shares of Anika Therapeutics by 5.2% in the fourth quarter. Thrivent Financial for Lutherans now owns 7,920 shares of the biotechnology company’s stock valued at $388,000 after buying an additional 390 shares in the last quarter. New England Research & Management Inc. purchased a new stake in shares of Anika Therapeutics during the first quarter valued at approximately $447,000. Finally, Atria Investments LLC increased its stake in shares of Anika Therapeutics by 13.9% in the first quarter. Atria Investments LLC now owns 5,563 shares of the biotechnology company’s stock valued at $242,000 after buying an additional 679 shares in the last quarter. Institutional investors own 81.27% of the company’s stock.

ANIK has been the subject of a number of recent research reports. Zacks Investment Research downgraded Anika Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, May 8th. BidaskClub raised Anika Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday.

About Anika Therapeutics

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.